ProKidney to Participate in Two Upcoming Conferences: Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare Conference

ProKidney Corp. (Nasdaq: PROK), a prominent player in the field of cellular therapeutics for chronic kidney disease (CKD), is set to engage with the investment community at two notable healthcare conferences in November 2025. These engagements are pivotal for the company as it advances its innovative solutions aimed at treating CKD, a condition affecting millions globally.

The company's management is scheduled to participate in the Guggenheim Healthcare Innovation Conference, taking place in Boston on November 12, 2025. The appearance will feature a fireside chat format at 10:00 AM ET, where senior executives will likely share insights into ProKidney’s strategic vision, ongoing clinical trials, and future growth prospects. A live webcast of this discussion will be available on the company’s website under the Investor Relations section.

Following this event, ProKidney will also attend the Jefferies Global Healthcare Conference from November 17 to 20, 2025, in London, where the team will conduct one-on-one meetings. Investors interested in discussing collaboration or investment opportunities during this event can arrange meetings through their banking representatives.

ProKidney is at the forefront of CKD treatment, with its lead product candidate, rilparencel (REACT®), currently undergoing Phase 3 clinical trials. This groundbreaking cellular therapy aims to preserve kidney function in patients who also have type 2 diabetes, showcasing the company's commitment to advancing regenerative medicine.

As ProKidney prepares for these conferences, it seeks to bolster its presence in the healthcare landscape, attract potential investors, and drive awareness of its innovative therapeutic approaches. For more information about the company and its initiatives, stakeholders can visit www.prokidney.com.

ProKidney Corp. (Nasdaq: PROK) is poised for notable visibility with its participation in two leading healthcare conferences this November—the Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare Conference. As a late clinical-stage cellular therapeutics company specializing in chronic kidney disease (CKD), ProKidney is at a crucial juncture, particularly as it strives to bring its innovative treatment, rilparencel, to market.

Engagement in these conferences offers ProKidney an opportunity to showcase its cutting-edge advancements in cellular therapy and articulate its strategic vision to investors and industry stakeholders. Highlighting the ongoing Phase 3 REGEN-006 study, management's discussions will likely delve into the potential of rilparencel to preserve kidney function in patients with advanced CKD and type 2 diabetes. This candid dialogue could ignite investor confidence and foster interest in the stock ahead of potential clinical trial outcomes, expected in the near future.

For investors, keeping an eye on ProKidney’s performance during and after these events is critical. The Guggenheim fireside chat on November 12th will provide real-time insights into management’s strategies and its outlook on the CKD market, while the Jefferies conference will facilitate personalized engagements, creating pathways for deeper investor understanding and support.

Given the rising prevalence of CKD, driven by factors such as aging populations and increasing diabetes rates, ProKidney stands at the forefront of a burgeoning market. The company's innovative approach, underscored by regulatory designations, highlights its potential as a transformative player.

In summary, investors should monitor ProKidney’s conference participation closely as it may be a catalyst for stock movement, reflecting broader market sentiment and operational performance. This dual conference participation marks an important moment for the company's visibility and stakeholder engagement, essential for fostering future growth.